Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Oct 18;62(11):3647–3655. doi: 10.2337/db13-0795

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2013 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

PMC Copyright notice

FIG. 2. — Podocyte injury resulting from VEGFR-2 inhibition in vivo. Reprinted with permission from Advani et al. (29), copyright (2007) National Academy of Sciences, U.S.A. Transmission electron micrographs of representative podocytes from vehicle-treated animals. Sprague-Dawley (SD) rat (A), spontaneously hypertensive rat (SHR) (B), and transgenic TGR(mRen-2)27 rat (C). After VEGFR-2 inhibition with the small molecule vandetanib, SD rat (D), SHR (E), and TGR(mRen-2)27 rat (F). Among vandetanib-treated groups, SD rats had occasional podocyte pseudocysts (*); SHRs showed a predominance of proteinaceous adsorption droplets (arrow), with occasional foot process fusion (arrowhead); and TGR(mRen-2)27 rats demonstrated severe podocyte injury with abundant adsorption droplet accumulation and some foot process fusion (arrowhead). Original magnification ×6,600.